Clinical Trial Update: Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of TH-302 in combination with sunitinib for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Pancreatic Neuroendocrine Tumor
• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)
• TH-302 (evofosfamide)

Snippet

Sponsor: Threshold Pharmaceuticals | Conditions: Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors | Phase 1 | Status: UNKNOWN